The subgroup of patients displaying high CCNE1 expression after primary cancer treatment was strongly (p = 0.000021) associated with reduced disease-free survival (DFS), pointing to enhanced risk for postcurative mortality in these patients (Figure 6b). The gene discussed is CCNE1; the disease is cancer.